All Search Results
News Releases
Aug 28, 2026, 07:00 ET CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
populations, delivery systems, CAR architectures, expression profiles, dosing strategies, and disease settings.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells
More news about: CREATE Medicines, Inc.
Jul 31, 2026, 07:00 ET CREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash University
vivo cell therapies and pairing our LNP technology with CREATE's platform is a powerful step toward solving it."About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Jul 30, 2026, 07:00 ET CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
administration paradigm. In preclinical studies, CRT-402 demonstrated deep and durable B cell depletion in nonhuman primates.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Jul 27, 2026, 06:00 ET Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
advancement of a potential novel therapy that, if approved, could reshape the treatment landscape for atopic dermatitis.""We founded Bambusa to create medicines that could redefine the standard of care, rather than deliver incremental improvement," said Shanshan Xu, M.D., Ph.D., Co-Founder and Chief Executive
More news about: Bambusa Therapeutics
May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
University of Wisconsin. He is a member of the PhRMA Advisory Committee and has served on White House OSTP committees.About CREATE MedicinesCREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly
More news about: CREATE Medicines, Inc.
